NIH and NASA Announce QuSAFE Challenge to Advance Quantum Sensing for Drug Safety

The National Institutes of Health (NIH) and NASA have announced the Quantum-Enabled Predictive Preclinical NAMs for Toxicity and Safety (QuSAFE) Challenge. This collaborative initiative aims to advance quantum-enabled sensing for in vitro New Approach Methodologies (NAMs), including organoids and microphysiological systems (MPS), with the goal of improving drug safety testing while reducing reliance on animal use.

According to the announcement, in vitro NAMs generate human-relevant data for drug development and safety evaluation. However, conventional assays and imaging often face limitations such as noise, invasiveness, and insufficient sensitivity. These constraints can cause weak, early, and low-abundance biological signals to go undetected, while destructive measurements hinder the monitoring of dynamic processes over time. Quantum-enabled sensing approaches are intended to offer ultra-high sensitivity, improved signal-to-noise performance, and nanoscale resolution to address these measurement challenges.

The QuSAFE Challenge supports NASA’s Biological and Physical Sciences Division by addressing the need for advanced detection methods beyond traditional laboratory settings. By utilizing recent developments in sensor research, the challenge is designed to enhance space exploration capabilities while yielding scientific benefits for both space and Earth applications.

Key Dates and Timeline

• Submissions Open Date: December 15, 2026
• Submissions Close Date: July 27, 2027

Practical Implications and Verification

The initiative seeks to bridge gaps in current preclinical testing methodologies by exploring quantum-sensing technologies. Participants and interested parties can review official guidelines, registration details, rules, and eligibility requirements directly on the official challenge website at https://www.qusafechallenge.com/